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There are few long-term reports of patients with frequent PVCs in the absence of ischemic
heart disease. In 86 patients without ischemic heart disease, who had 1000 or more PVCs in
24-hour Holter ECG, the number of PVCs during 24-hours Holter ECG and echocardio-
graphic parameters were followed at least 1 year (66:5 39:7 months). PVC was signiﬁcantly
reduced in the patients with or without underlying diseases (UD). The reduction rate in the
number of PVCs was prominent in patients with UD. PVC was signiﬁcantly reduced in
patients under medication, but not in patients without medication. In the comparison between
the initial and follow up observation using Wilcoxon’s rank test, the number of PVC was
signiﬁcantly reduced (P < 0:05), and EF was also improved (P < 0:05) in angiotensin
converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) group, and in -
blocker group. In Ca-antagonist group and antiarrhythmic drug group, the number of PVCs
was also signiﬁcantly reduced (P < 0:05). Multivariate analysis revealed signiﬁcantly higher
incidence (60% or more with PVC reduction) in ACEI/ARB group.
These results suggest that the administration of ACEI/ARB may contribute to the reduction
of PVC in non-ischemic heart disease cases with multiple PVC.
(J Arrhythmia 2008; 24: 18–25)
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Introduction
Since the Cardiac Arrhythmia Suppression Trial
(CAST),1) many reports have discussed the prognosis
of premature ventricular contraction (PVC) in
ischemic heart disease patients,2–5) but only a few
studies exist of the long-term prognosis of PVC in
patients without ischemic heart disease. There is a
high risk of sudden death in young hypertrophic
cardiomyopathy (HCM) patients with non-sustained
ventricular tachycardia (NSVT),6) and poor prognosis
for dilated cardiomyopathy (DCM) patients with
NSVT.7) It is widely accepted that PVC without
underlying disease is benign and does not require
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treatment,8) but several recent reports have found that
cases with frequent PVCs show cardiac hypofunc-
tion, which is improved by ablation treatment.9,10)
In the present study, the severity of PVC and
cardiac function were followed up in patients with
frequent PVCs and without ischemic heart disease,
and the eﬀect of therapeutic drugs on these param-
eters was examined.
Methods
Of 5932 patients who underwent initial Holter
electrocardiography (ECG) at our hospital between
January 1995 and December 2002, 552 patients had
1000 or more PVCs. 335 patients were excluded
because of ischemic heart disease (diagnosed by
clinical history, echocardiography, exercise test or
cardio angiography). Of the remaining 217 patients,
88 patients had follow-up Holter ECG assessment at
interval of 12 months or longer from the initial
Holter ECG. 2 patients who were not able to
continue sustainable treatment before the last follow
up Holter ECG were excluded. Consequently, 86
subjects (mean age 57 15 years; 57 males, 29
females) were enrolled.
Background factors
The background factors investigated retrospec-
tively were the presence or absence of underlying
disease, and presence or absence of administered
medications. The types of medication considered
were Ca-antagonists (except group IV drugs in the
Vaughan-Williams classiﬁcation), -blockers, angio-
tensin converting enzyme inhibitor (ACEI), angio-
tensin receptor blocker (ARB) and antiarrhythmic
drugs (including group IV drugs in the Vaughan-
Williams classiﬁcation). The medications were de-
ﬁned as which had been continuously administered
for at least 1 year before the follow-up assessment by
Holter ECG and Echocardiography.
Holter ECG
The follow-up Holter ECG (43420B Holter, HP
Company, USA or DMW-7000H, Fukuda denshi,
Japan) was taken at least 1 year after the initial
Holter ECG. We made the following observations on
the initial and follow-up Holter ECG: Change in the
number of PVC during 24 hours, the reduction rate
in the number of PVC [calculated as (number of
PVC at the end of observation  number of PVC at
the start of observation)  100/number of PVC at
the start of observation], circadian variation of PVC
appearance (all-day type, daytime type and nighttime
type), the presence or absence of repetition, and
patterns of PVC appearance. We deﬁned the patients
with reduced PVC group as patients who had a
reduction rate of 60% greater in the follow up Holter
ECG compared to the initial Holter ECG. The prev-
alence of reduced PVC group according to medi-
cation was examined using multivariate analysis.
Echocardiography
The echocardiography performed within 1 month
of the initial Holter ECG was used for the initial
evaluation, and follow-up echocardiography was
performed at least one year after the initial Holter
ECG and the initial echocardiography. We measured
the left ventricular end-diastolic dimension (LVDd),
left ventricular end-systolic dimension (LVDs) and
left ventricular ejection fraction (EF) calculated
using the Teichholz method. We divided patients
into improved or constant EF group and reduced EF
group, and evaluated the eﬀect of treatment on
cardiac function.
Statistical analysis
Continuous variables were expressed as mean
 standard deviation (SD). The chi-square test was
used to compare the rate of drug administration
between the two groups. Wilcoxon’s rank test was
used to compare initial and follow-up mean value of
the number of PVCs and the LVDd, LVDs and EF.
For comparison of the reduction rate in the number
of PVCs (initial to follow-up) between groups, the
Mann-Whitney U test was used. Multivariate analy-
sis was used to examine the impact of the type of
medications on the incidence of patients who had
60% or more reduction of PVC and on the improve-
ment of EF. A diﬀerence at a risk rate below 5% was
considered signiﬁcant.
Results
Underlying diseases
A total of 51 patients had underlying diseases,
including hypertension in 23, atrial ﬁbrillation in 10,
sick sinus syndrome in 5, valvular heart disease in 6,
DCM in 2 and HCM in 5 (Group UD); 35 patients
had no underlying diseases (Group NUD).
Presence or absence of medications and the
types of medications
All patients were not administered any medication
investigated in this study at the initial observation.
After initial Holter ECG, medications investigated in
this study were administered in 62 of the 86 patients.
A total of 19 out of 35 patients in Group NUD, and
43 of 51 in Group UD, were given medications; the
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rate of patient administered medication was higher in
Group UD (P < 0:001). These medications consisted
of Ca-antagonists in 23 (monotherapy in 8), -
blockers in 30 (monotherapy in 7), ACEI or ARB
(ACEI/ARB) in 17 (monotherapy in 4), and antiar-
rhythmic drugs in 29 patients (monotherapy in 12).
The antiarrhythmic drugs were in Vaughan-Williams
classiﬁcation group Ia in 8 patients (pirmenol in 5,
disopyramide in 1, and cibenzoline in 2), group Ib in
13 (mexiletine in 9 and aprindine in 4), group Ic in 1
(pilsicainide), group III in 5 (amiodarone in 3, sotalol
in 1, and bepridil in 1), and group IV in 2 (both
verapamil). Thirty one patients were administrated 2
or more drugs and 24 patients were not administrated
any medication considered in this study.
Holter ECG
Figure 1 shows the distribution of the number of
PVCs during 24 hours of the initial Holter ECG
recording in all patients. In the 86 patients, the
number of PVC was less than 10,000 per day in 57
(66.3%), 10,000 to 20,000 per day in 16 (18.6%),
and equal or more than 20,001 per day in 13
(15.1%). For the patterns of PVC appearance, single
PVC was seen in 44 patients (the PVC was multi-
focal in 6 of these 44), couplet of PVC in 23, and
non-sustained ventricular tachycardia (3–5 consec-
utive PVCs) in 19 patients. None of the patients had
ventricular tachycardia with 6 or more consecutive
PVCs. For circadian variation of PVC, the all-day,
daytime and nighttime types were recognized in 72,
13 and 1 patient, respectively.
Follow-up Holter ECG was undertaken at a mean
interval of 66:5 39:7 months from the initial
Holter ECG. Table 1 shows the number of PVCs on
the initial and follow-up Holter ECGs. The number
of PVC at the follow-up was signiﬁcantly (P <
0:0001) less than at the initial observation.
Table 2 shows changes in the number of PVCs in
Groups UD (mean follow up interval: 76:4 40:0
months) and NUD (mean follow up interval: 50:0
36:1 months). In both groups, the number of PVC
at the follow-up was signiﬁcantly less than at the
initial observation. The reduction rate was signiﬁ-
cantly higher (P ¼ 0:025) in Group UD than in
Group NUD. The prevalence of patients in the
reduced PVC group was signiﬁcantly higher in UD
group.
Table 3 shows changes in the number of PVCs
in groups with and without medication (Table 3). In
the group without drug administration, the number
of PVC at the follow-up did not diﬀer signiﬁcantly
from that at the initial observation (mean follow up
interval: 56:4 37:4 months). In the groups receiv-
ing medications, the number of PVC at the follow-up
was signiﬁcantly lower (P < 0:0001) than at the
initial observation (mean follow up interval: 69:9
41:5 months).
Table 4 shows changes in the number of PVCs
between the initial and follow up observation in
patients given Ca-antagonists (mean follow up
interval: 76:2 32:4 months), -blockers (mean
follow up interval: 60:3 35:6 months), ACEI/
ARB (mean follow up interval: 86:9 40:9 months)
and antiarrhythmic drugs (mean follow up interval:
65:0 47:2 months). In all groups receiving drugs,
the number of PVCs at the follow-up was signiﬁ-
cantly less than at the initial observation. Multi-
variate analysis shows that the prevalence of the
patients who had 60% or more reduction of PVCs
N
u
m
be
r 
o
f P
at
ie
nt
s
0
5
10
15
20
25
30
0 10000 20000 30000 40000 50000 60000
Number of PVCs
9915±11138/day
Figure 1 Frequency distribution of the number of PVC on
24-hour Holter ECG (n ¼ 86).
Table 1 Changes in the number of PVC on 24-hour Holter
ECG and in UCG ﬁndings.
Variable All cases
(N ¼ 86)
Initial Follow up P
Number of
PVC (/day) 9915 11138 5461 11023 P < 0:0001
Reduction rate
of PVC (%) 27:0 187:6
60% or more
reduced PVC 54/86
PVC increase 12/86
UCG
LVDd (mm) 49:9 7:4 49:8 6:6 NS
LVDs (mm) 31:6 9:3 32:2 7:6 NS
EF (%) 63:1 13:0 63:9 10:8 NS
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was signiﬁcant in patients treated with ACEI/ARB
but not in patients treated with other types of
medications (Figure 2).
Five of 13 patients with the daytime type of
circadian variation of PVC received -blockers;
4 of these 5 underwent strong responses to these
drugs, with a reduction from 13274 18086/day to
517 514/day. The -blocker was ineﬀective in
one patient.
Echocardiography
The mean EF for all patients at the start of
observation was 63:1 13:0, and cardiac hypofunc-
tion (speciﬁed as EF below 40%) was recognized in
6 of the 86 patients; of these, 3 had valvular heart
disease, 2 had DCM and one had hypertension.
There were no signiﬁcant changes from initial
value to follow-up in LVDd, LVDs and EF in all 86
patients (Table 1).
No signiﬁcant changes from initial value to
follow-up were observed in LVDd, LVDs and EF
in Group UD, Group NUD, the group administered
drugs, and the group not given drug treatment
(Tables 2 and 3).
Table 4 shows changes in LVDd, LVDs and EF
between the initial and follow up observation with
each type of drug administered. EF was signiﬁcantly
improved at the follow-up, compared to the initial
observation, with administration of ACEI/ARB and
-blocker, but was not improved by administration
of Ca-antagonist or antiarrhythmic drugs. There was
no signiﬁcant change from initial value to follow-up
Table 2 Changes in the number of PVC on 24-hour Holter ECG and in UCG ﬁndings according to the presence/absence of
structural heart disease.
Variable UD group
(N ¼ 51)
Non-UD group
(N ¼ 35)
Initial Follow up P Initial Follow up P
Number of
PVC (/day) 7786 9049 2706 6741 P < 0:0001 13017 13154 9478 14454 P ¼ 0:048
Reduction rate
of PVC (%) 51:3 162:3 þ8:4 216:9
P ¼ 0:025
60% or more
reduced PVC 38/51 16/35 P ¼ 0:013
PVC increase 2/51 10/35 P ¼ 0:013
UCG
LVDd (mm) 50:9 8:3 50:2 7:8 NS 48:4 5:7 49:2 4:5 NS
LVDs (mm) 32:5 11:2 32:7 8:9 NS 30:3 5:5 31:4 5:1 NS
EF (%) 61:4 14:3 63:6 11:8 NS 65:7 10:5 64:3 9:3 NS
reduction rate of PVC was signiﬁcantly higher in UD group
Table 3 Changes in the number of PVC on 24-hour Holter ECG and in UCG ﬁndings according to the presence/absence of
administered medication.
Variable medication
(N ¼ 62)
Non-medication
(N ¼ 24)
Initial Follow up P Initial Follow up P
Number of
PVC (/day) 10397 10641 3880 8073 P < 0:0001 9280 12757 9278 15999 NS
Reduction rate
of PVC (%) 49:6 153:7 þ21:6 251:2
P < 0:0001
60% or more
reduced PVC 42/62 12/24 P ¼ 0:013
PVC increase 4/62 8/24 P ¼ 0:013
UCG
LVDd (mm) 50:6 7:7 50:1 6:9 NS 48:0 6:9 49:3 6:2 NS
LVDs (mm) 32:6 10:4 32:3 8:4 NS 29:2 5:8 32:1 5:9 NS
EF (%) 61:3 14:5 64:0 12:0 NS 67:6 7:1 63:2 7:7 NS
reduction rate of PVC was signiﬁcantly higher in medication group
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in LVDd and LVDs with the administration of any
type of drug. Multivariate analysis shows that the
incidence of improvement of EF in the patients
treated with any types of medications was not
signiﬁcant (Figure 2).
Discussion
According to the CAST report,1) when antiar-
rhythmic drugs such as ﬂecainide and encainide were
administered for the treatment of asymptomatic or
mildly symptomatic ventricular arrhythmia occur-
ring following myocardial infarction, the mortality
rate was signiﬁcantly higher in patients given these
drugs than in the placebo group. Administration of
antiarrhythmic drugs appears to worsen prognosis,
and physicians’ attention was called to conventional
drug therapy for arrhythmia. The present study
included only patients with non-ischemic heart
diseases and those with frequent PVC (at least
1000 PVC per day). In these patients, the number of
PVCs decreased signiﬁcantly following long-term
observation for 66:5 39:7 months on average
without worsening of EF.
The number of PVCs was reduced in patients
who received the drugs investigated in this study,
whereas there was no signiﬁcant reduction in the
number of PVC in patients who did not receive
these drugs. The overall reduction in the number of
PVC therefore appears mainly to be because these
medications were administered to 62 (72%) of the
86 patients. Since the proportion of patients
receiving these drugs was larger in Group UD
(43/51) than in Group NUD (19/35), the rate of
reduction in PVC number was higher in the former.
These results implied that the higher reduction rate
of PVC in group UD was attributed to the higher
prevalence of medicated patients than in group
NUD, while the lower prevalence of medicated
patients lowered the reduction rate of PVC in
Group NUD.
In comparison between the initial and the follow
up Holter ECG, a reduction in the number of PVC
was observed with the administration of all types
Table 4 Changes in the number of PVC on 24-hour Holter ECG and in UCG ﬁndings according to medication administration.
Variable Ca-antagonist
(N ¼ 23)
-blocker
(N ¼ 30)
Initial Follow up P Initial Follow up P
Number of
PVC (/day) 12094 12022 3844 9102 P ¼ 0:0002 11645 10630 3798 7199 P ¼ 0:0005
Reduction rate
of PVC (%) 38:9 224:6 21:1 224:9
60% or more
reduced PVC 17/23 20/30
PVC increase 1/23 2/30
UCG
LVDd (mm) 50:0 6:7 47:8 4:5 NS 51:9 9:3 50:5 7:1 NS
LVDs (mm) 31:5 9:7 28:9 4:5 NS 33:0 13:4 32:6 7:5 NS
EF (%) 64:9 15:0 69:0 0:08 NS 59:1 15:9 64:7 9:0 P < 0:05
Variable ACE/ARB
(N ¼ 17)
AAD
(N ¼ 29)
Initial Follow up P Initial Follow up P
Number of
PVC (/day) 8468 8274 965 1832 P ¼ 0:0003 9200 9863 3472 7894 P < 0:0001
Reduction rate
of PVC (%) 88:6 15:2 75:1 33:6
60% or more
reduced PVC 17/17 17/30
PVC increase 0/17 1/29
UCG
LVDd (mm) 50:1 9:5 51:6 9:4 NS 50:8 9:7 50:6 7:5 NS
LVDs (mm) 34:7 13:4 34:6 11:7 NS 33:8 12:3 33:0 10:2 NS
EF (%) 54:2 17:5 61:7 16:2 P < 0:01 60:1 17:6 62:4 14:8 NS
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of drugs (Ca-antagonist, -blocker, ACEI/ARB and
antiarrhythmic drugs) by Wilcoxon’s rank test.
However, multivariate analysis shows that the
incidence of the patients who had 60% or more
reduction of PVC was signiﬁcant in patients treated
with ACEI/ARB but not in patients treated with
other types of medications.
In considering the eﬃcacy of Ca-antagonists,
one report found that severe arrhythmia in senile
hypertension patients was reduced by these
drugs,11) but no reports have asserted a direct
antiarrhythmic action of Ca-antagonists. However,
another study found that a Ca-antagonist causes
regression of left ventricular hypertrophy.12) These
observations suggest that Ca-antagonists improve
the myocardium by structural and electrical remod-
eling, and also that the number of PVC was
indirectly decreased by the administration of these
drugs.
-blockers have been found to decrease the
number of PVC. In considering the daytime type of
circadian PVC appearance, many reports have
shown that -blockers reduce the number of such
PVCs.13) In the present study also, the daytime type
of PVC, of which the number is believed to decrease
via suppression of sympathetic activity, was recog-
nized in 13 patients. Five of these 13 received -
blockers, and the number of PVCs decreased
markedly in 4 of these. We found that EF at the
follow-up was signiﬁcantly improved over that at the
initial observation due to -blocker administration
by Wilcoxon’s rank test. In conventional large-scale
studies, EF improved dose-dependently with admin-
istration of -blockers to patients with heart fail-
ure.14,15) In our present study, EF at the start of
observations was 59:1 15:9% in the -blocker
administration groups, a value that does not indicate
the state of heart failure.
Since the CAST study there has been controversy
over the appropriateness of antiarrhythmic drugs.
The CAST included many patients with EF less than
40% after myocardial infarction, whereas the present
subjects had no history of ischemic heart disease
and had a mean EF of 60:1 17:6% at the initial
observation. EF was below 40% in 6 of our 86
patients. Antiarrhythmic drugs were administered to
29 patients. [Vaughan-Williams classiﬁcation group
Ia in 8 patients, group Ib in 13, group Ic in 1, group
III in 5 and group IV in 2 patients] Class I drugs
(Ia, Ib or Ic) were administered in 22 patients. By
Wilcoxon’s rank test, signiﬁcant reduction of num-
ber of PVCs by administration of antiarrhythmic
drug was observed without worsening EF in these
patients.
Odds Ratio 95%CI P value
Ca-antagonist
ACE/ARB
AAD
Odds Ratio 95%CI P value
Ca-antagonist
β -blocker
β -blocker
ACE/ARB
AAD
the incidence of patients with 60% or more reduced PVC
the incidence of improvement of EF
2.90 0.88–9.53 0.80
0.69 0.23–2.07 0.51
12.7 1.51–106.97 0.02
1.03 0.35–3.01 0.95
1.52 0.53–4.32 0.43
1.70 0.61–4.77 0.31
3.01 0.77–12.43 0.11
1.02 0.37–2.84 0.97
-1.0 1.0 3.0 5.0 7.0 9.0 11.0 13.0 15.0 17.0 19.0
-1.0 1.0 3.0 5.0 7.0 9.0 11.0 13.0 15.0
Figure 2 Multiple classiﬁcation analysis of the incidence of reduced PVC and improvement of EF.
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Previous studies have shown the frequency of
NSVT in patients with frequent PVC is signiﬁcantly
reduced by administration of ACEI/ARB.16) Several
mechanisms are believed to be involved in this
decrease: (1) suppression of triggered activity17,18)
based on a delayed after depolarization, due to
intracellular Ca increase with the opening of the
angiotensin II receptor-operated Ca channel; (2)
suppressed shortening of the myocardial refractory
period, through an increase19) in intracellular con-
duction velocity due in turn to the decrease in
intracellular electrical resistance caused by angio-
tensin II;20) (3) suppression of sympathetic nerve
activation by angiotensin II.21) In the present study,
the number of PVCs was reduced and EF was
increased in the comparison between the initial and
follow up observation by Wilcoxon’s rank test. As
well as the direct antiarrhythmic action of ACEI/
ARB, the improvement in cardiac function, as
indicated by V-HeFT II,22) may be indirectly
involved in the reduced number of PVC.
Although the study population might be too
small to estimate the eﬀect of type of drugs on
improvement of cardiac function using multivariate
analysis, our results suggest that ACEI and ARB are
the most eﬀective types of drugs to reduce PVC.
Some reports have found an improvement of
cardiac function in patients with frequent PVC
through catheter ablation.9,10) In regard to the mech-
anism of deterioration of cardiac function in frequent
PVC patients, possible explanations include the
morbid condition due to ineﬀective contraction
during PVC, a condition resembling bradycardic
heart failure,23) and asynchrony at the time of PVC
appearance.24) Overall, the number of PVCs was
decreased without catheter ablation, and cardiac
function was preserved. Especially, the number of
PVC was more signiﬁcantly decreased in the patients
with underlying disease who received pharmacolog-
ical therapy for underlying disease. These results
indicate the eﬀectiveness of the therapy itself for the
underlying disease; however there are the issues of
reproducibility and daily variance of PVC, in addition
to the reduction of the number of PVCs realized.
In this study, multivariate analysis showed that the
prevalence of the patients who had 60% or more
reduction of PVC was signiﬁcant in patients treated
with ACEI/ARB, but not in patients treated with
anti-arrhythmia drugs. According to the report
mentioned the above, cardiac function might be
reduced by frequent PVCs. Considering the negative
inotropic eﬀect of antiarrhythmic drugs, the admin-
istration of antiarrhythmic drugs may cause deteri-
oration of cardiac function in addition to reduced
cardiac function caused by frequent PVCs. In this
study, ACEI/ARB was not administered in patients
without underlying disease. However, the adminis-
tration of ACEI/ARB might be considered even in
normal cardiac function without underlying disease
instead of antiarrhythmic drugs, because of direct
antiarrhythmic eﬀect and the ameliorating eﬀect for
cardiac function of ACEI/ARB.
In contrast to catheter ablation and antiarrhythmic
drug treatments for such arrhythmias, i.e., down-
stream treatment, the value of treating the cause of
arrhythmia, so-called upstream treatment, has also
been considered in recent years. In particular,
administration of ACEI/ARB suppresses remodeling
of the atrium as an upstream treatment aimed at
suppressing atrial ﬁbrillation.25) Although signiﬁcant
improvement of EF was not conﬁrmed by multi-
variate analysis, administration of ACEI/ARB sig-
niﬁcantly improved EF at the follow up UCG by
Wilcoxon’s rank test. This ﬁnding suggests that
ACEI/ARB is considered to have the eﬀect of a
downstream treatment, based on the action described
earlier, but may act as upstream treatment drugs
which improve hemodynamics and have an eﬀect on
myocardial remodeling.
Limitations
Our study was retrospective. In selection of drugs,
treatment of underlying diseases took priority over
other options, and the study could not be randomized
in the limited number of patients involved.
In many of our subjects, Holter ECG was
conducted only at the start and the end of observa-
tion, and reproducibility was poor. Prospective
randomized examinations in a larger number of
patients would be superior.
In this study, 31 of 62 patients with two or more
medicines were included in the medication group.
Moreover, there is variety in patients’ cardiac
functions and underlying disease. The change in
number of PVCs between the initial and follow up
Holter ECG may not reﬂect only the eﬀect of single
medicine, but also the inﬂuence of a combined
therapy for underlying disease.
Conclusion
Non-ischemic heart disease cases with multiple
PVC were observed for long term periods. The
number of PVCs was decreased by the therapy given
to treat the underlying disease. The administration of
ACEI/ARB may contribute to the reduction of PVC
by direct action on arrhythmia or by preventing
cardiac remodeling as an upstream treatment.
J Arrhythmia Vol 24 No 1 2008
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